title: Is riluzole a potential therapy for Rett syndrome?
abstract: Rett syndrome (RTT) is a severe neurodevelopmental disorder with autistic features and is caused by loss-of-function mutations in the gene encoding methyl-CpG-binding protein 2 (MECP2) in the majority of cases. Besides symptomatic treatment, no therapeutic trials have shown effectiveness for RTT. Some perspectives in the treatment of RTT have been provided by recent works showing a phenotypic reversal by increasing brain-derived neurotrophic factor (BDNF) expression in a RTT mouse model. Glutamate may also play an important role in the primary pathogenesis in Rett syndrome through the excitotoxic neuronal injury in experimental models. Riluzole, an agent currently approved for the treatment of amyotrophic lateral sclerosis, is a glutamatergic modulator and BDNF enhancer with neuroprotective properties. For these reasons, riluzole could potentially play an important role in the treatment of RTT symptoms. Several points regarding the use of riluzole in RTT are discussed. Further evaluation of the therapeutic effects of this agent in RTT animal models is needed before clinical trials can begin.
authors: Department of Psychiatry, Taipei Veterans General Hospital, Taiwan; Division of Psychiatry, School of Medicine, National Yang-Ming University, Taiwan. Electronic address: tsai610913@gmail.com.
authors: Shih-Jen
authors: SJ
authors: Tsai
mesh_terms: D006801:Humans; D008962:Models, Theoretical; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D015518:Rett Syndrome / Q000188:drug therapy*; D019782:Riluzole / Q000627:therapeutic use*
chemical_list: D018696:Neuroprotective Agents; D019782:Riluzole